1. Home
  2. BNC vs VCRE Comparison

BNC vs VCRE Comparison

Compare BNC & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CEA Industries Inc.

BNC

CEA Industries Inc.

HOLD

Current Price

$3.61

Market Cap

287.3M

Sector

Industrials

ML Signal

HOLD

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

SELL

Current Price

$10.50

Market Cap

271.7M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
BNC
VCRE
Founded
N/A
2000
Country
United States
Sweden
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
287.3M
271.7M
IPO Year
2010
2026

Fundamental Metrics

Financial Performance
Metric
BNC
VCRE
Price
$3.61
$10.50
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $24.37
AVG Volume (30 Days)
★ 739.1K
17.0K
Earning Date
12-14-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 159.72
N/A
EPS
N/A
★ N/A
Revenue
★ $9,581,968.00
N/A
Revenue This Year
$27.15
$38.94
Revenue Next Year
$6.70
$694.23
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 32.89
N/A
52 Week Low
$1.84
$7.88
52 Week High
$7.72
$14.01

Technical Indicators

Market Signals
Indicator
BNC
VCRE
Relative Strength Index (RSI) 32.67 54.19
Support Level $2.73 $10.56
Resistance Level $4.14 $11.88
Average True Range (ATR) 0.26 0.42
MACD -0.14 0.12
Stochastic Oscillator 0.66 63.71

Price Performance

Historical Comparison
BNC
VCRE

About BNC CEA Industries Inc.

CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: